What FDA safety alerts have been issued for medications used in the treatment of age-related macular degeneration (AMD)?

Updated: Dec 12, 2018
  • Author: Lucia Sobrin, MD, MPH; Chief Editor: Karl S Roth, MD  more...
  • Print
Answer

Answer

The FDA issued a safety alert regarding repackaged intravitreal injections of bevacizumab (Avastin), an anti-VEGF antibody. Infections resulted from contamination that occurred during the repackaging of bevacizumab from 100 mg/4 mL single-use, preservative-free vials into individual 1-mL syringes for off-label use to treat wet macular degeneration. [31]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!